The European Medicines Agency granted Orphan Drug Designation to Debio 1143 for treatment of ovarian cancer. Debio 1143 is an oral, small molecule inhibitor of apoptosis proteins with a dual pro-apoptotic and immunomodulatory mode of action developed as a potent chemo/radiosensitizer in oncology. Further to the encouraging signs of efficacy seen in clinical phase I...
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
